{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:48:29Z","timestamp":1792784909354,"version":"4.5.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T00:00:00Z","timestamp":1669680000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T00:00:00Z","timestamp":1669680000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"\u201cRevitalizing Liaoning Talents Plan\u201d and was also sponsored by Outstanding Scientific Fund of Shengjing Hospital of China Medical University."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Parkinsons Dis."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Biomarkers play important roles in the diagnosis and differential diagnosis of Parkinson\u2019s disease (PD). Thus, we carried out a systematic review and meta-analysis evaluating the diagnostic utility of cerebrospinal fluid (CSF) biomarkers to distinguish PD from atypical parkinsonian syndromes (APSs) and controls. Data for PD and APS and controls were extracted from 123 studies that reported the concentration of CSF biomarkers. Comparisons were presented using pooled Hedges\u2019\n                    <jats:italic>g<\/jats:italic>\n                    . Sources of heterogeneity were evaluated using meta-regression, and subgroup and sensitivity analyses. We found that compared with controls, PD patients had lower levels of amyloid beta 1-42, phosphorylated tau, total tau, total \u03b1-synuclein, Zn, DJ-1, and YKL-40, and higher levels of oligomeric and phosphorylated \u03b1-synuclein. Moreover, lower CSF levels of neurofilament light chain, t-tau, YKL-40, and C-reactive protein were found in PD patients compared to those with multiple system atrophy. PD patients also had lower levels of NFL and higher levels of A\u03b242 compared with patients with progressive supranuclear palsy. Reduced levels of p-tau and t-tau and higher A\u03b242 levels were found in PD patients compared with patients with dementia with Lewy bodies. Finally, reduced NFL levels were found in patients with PD compared with patients with cortical basal degeneration. Therefore, we believe that the combinations of t-\u03b1-syn, A\u03b242, and NFL could be promising biomarkers for the differential diagnosis of PD and APSs.\n                  <\/jats:p>","DOI":"10.1038\/s41531-022-00431-7","type":"journal-article","created":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T06:03:12Z","timestamp":1669701792000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["A meta-analysis of the diagnostic utility of biomarkers in cerebrospinal fluid in Parkinson\u2019s disease"],"prefix":"10.1038","volume":"8","author":[{"given":"Chunchen","family":"Xiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengri","family":"Cong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoping","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuyan","family":"Cong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,29]]},"reference":[{"key":"431_CR1","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","volume":"386","author":"LV Kalia","year":"2015","unstructured":"Kalia, L. V. & Lang, A. E. Parkinson\u2019s disease. LANCET 386, 896\u2013912 (2015).","journal-title":"LANCET"},{"key":"431_CR2","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1001\/archneur.56.1.33","volume":"56","author":"DJ Gelb","year":"1999","unstructured":"Gelb, D. J., Oliver, E. & Gilman, S. Diagnostic criteria for Parkinson disease. Arch. Neurol. 56, 33\u201339 (1999).","journal-title":"Arch. Neurol."},{"key":"431_CR3","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1002\/mds.27110","volume":"32","author":"P Eusebi","year":"2017","unstructured":"Eusebi, P. et al. Diagnostic utility of cerebrospinal fluid alpha-synuclein in Parkinson\u2019s disease: a systematic review and meta-analysis. Mov. Disord. 32, 1389\u20131400 (2017).","journal-title":"Mov. Disord."},{"key":"431_CR4","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1212\/WNL.0000000000002350","volume":"86","author":"G Rizzo","year":"2016","unstructured":"Rizzo, G. et al. Accuracy of clinical diagnosis of Parkinson disease: a systematic review and meta-analysis. Neurology 86, 566\u2013576 (2016).","journal-title":"Neurology"},{"key":"431_CR5","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1016\/j.parkreldis.2014.04.019","volume":"20","author":"J Joutsa","year":"2014","unstructured":"Joutsa, J., Gardberg, M., Roytta, M. & Kaasinen, V. Diagnostic accuracy of parkinsonism syndromes by general neurologists. Parkinsonism Relat. Disord. 20, 840\u2013844 (2014).","journal-title":"Parkinsonism Relat. Disord."},{"key":"431_CR6","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CJ Jack","year":"2018","unstructured":"Jack, C. J. et al. NIA-AA Research Framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 14, 535\u2013562 (2018).","journal-title":"Alzheimers Dement."},{"key":"431_CR7","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1002\/mds.27897","volume":"35","author":"LP Oosterveld","year":"2020","unstructured":"Oosterveld, L. P. et al. CSF or serum neurofilament light added to alpha-synuclein panel discriminates Parkinson\u2019s from controls. Mov. Disord. 35, 288\u2013295 (2020).","journal-title":"Mov. Disord."},{"key":"431_CR8","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/S1474-4422(19)30024-9","volume":"18","author":"L Parnetti","year":"2019","unstructured":"Parnetti, L. et al. CSF and blood biomarkers for Parkinson\u2019s disease. Lancet Neurol. 18, 573\u2013586 (2019).","journal-title":"Lancet Neurol."},{"key":"431_CR9","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/S1474-4422(17)30328-9","volume":"16","author":"JC Latourelle","year":"2017","unstructured":"Latourelle, J. C. et al. Large-scale identification of clinical and genetic predictors of motor progression in patients with newly diagnosed Parkinson\u2019s disease: a longitudinal cohort study and validation. Lancet Neurol. 16, 908\u2013916 (2017).","journal-title":"Lancet Neurol."},{"key":"431_CR10","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.3233\/JAD-190615","volume":"72","author":"SY Wang","year":"2019","unstructured":"Wang, S. Y. et al. Neurofilament light chain in cerebrospinal fluid and blood as a biomarker for neurodegenerative diseases: a systematic review and meta-analysis. J. Alzheimers Dis. 72, 1353\u20131361 (2019).","journal-title":"J. Alzheimers Dis."},{"key":"431_CR11","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1001\/jamaneurol.2019.1534","volume":"76","author":"C Bridel","year":"2019","unstructured":"Bridel, C. et al. Diagnostic value of cerebrospinal fluid neurofilament light protein in neurology: a systematic review and meta-analysis. JAMA Neurol. 76, 1035\u20131048 (2019).","journal-title":"JAMA Neurol."},{"key":"431_CR12","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1212\/WNL.0000000000004609","volume":"89","author":"B Mollenhauer","year":"2017","unstructured":"Mollenhauer, B. et al. Longitudinal CSF biomarkers in patients with early Parkinson disease and healthy controls. Neurology 89, 1959\u20131969 (2017).","journal-title":"Neurology"},{"key":"431_CR13","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.nbd.2010.10.005","volume":"41","author":"ME Kalaitzakis","year":"2011","unstructured":"Kalaitzakis, M. E., Walls, A. J., Pearce, R. K. & Gentleman, S. M. Striatal abeta peptide deposition mirrors dementia and differentiates DLB and PDD from other parkinsonian syndromes. Neurobiol. Dis. 41, 377\u2013384 (2011).","journal-title":"Neurobiol. Dis."},{"key":"431_CR14","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1007\/s00401-016-1552-2","volume":"131","author":"JH Kang","year":"2016","unstructured":"Kang, J. H. et al. CSF biomarkers associated with disease heterogeneity in early Parkinson\u2019s disease: the Parkinson\u2019s Progression Markers Initiative Study. Acta Neuropathol. 131, 935\u2013949 (2016).","journal-title":"Acta Neuropathol."},{"key":"431_CR15","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s40478-021-01175-w","volume":"9","author":"C Bargar","year":"2021","unstructured":"Bargar, C. et al. Streamlined alpha-synuclein RT-QUIC assay for various biospecimens in Parkinson\u2019s disease and dementia with Lewy bodies. Acta Neuropathol. Commun. 9, 62 (2021).","journal-title":"Acta Neuropathol. Commun."},{"key":"431_CR16","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/s41586-020-1984-7","volume":"578","author":"M Shahnawaz","year":"2020","unstructured":"Shahnawaz, M. et al. Discriminating alpha-synuclein strains in Parkinson\u2019s disease and multiple system atrophy. Nature 578, 273\u2013277 (2020).","journal-title":"Nature"},{"key":"431_CR17","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/nrn3406","volume":"14","author":"HA Lashuel","year":"2013","unstructured":"Lashuel, H. A., Overk, C. R., Oueslati, A. & Masliah, E. The many faces of \u03b1-synuclein: from structure and toxicity to therapeutic target. Nat. Rev. Neurosci. 14, 38\u201348 (2013).","journal-title":"Nat. Rev. Neurosci."},{"key":"431_CR18","doi-asserted-by":"publisher","first-page":"e827","DOI":"10.1212\/WNL.0000000000010084","volume":"95","author":"D Backstrom","year":"2020","unstructured":"Backstrom, D. et al. NFL as a biomarker for neurodegeneration and survival in Parkinson disease. Neurology 95, e827\u2013e838 (2020).","journal-title":"Neurology"},{"key":"431_CR19","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1136\/jnnp-2014-309562","volume":"86","author":"NK Magdalinou","year":"2015","unstructured":"Magdalinou, N. K. et al. A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes. J. Neurol. Neurosurg. Psychiatry 86, 1240\u20131247 (2015).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"431_CR20","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1126\/science.aav2546","volume":"363","author":"JK Holth","year":"2019","unstructured":"Holth, J. K. et al. The sleep-wake cycle regulates brain interstitial fluid tau in mice and CSF tau in humans. Science 363, 880\u2013884 (2019).","journal-title":"Science"},{"key":"431_CR21","doi-asserted-by":"publisher","first-page":"573","DOI":"10.3233\/JAD-200680","volume":"78","author":"H Jang","year":"2020","unstructured":"Jang, H. et al. The impact of amyloid-beta or tau on cognitive change in the presence of severe cerebrovascular disease. J. Alzhemers Dis. 78, 573\u2013585 (2020).","journal-title":"J. Alzhemers Dis."},{"key":"431_CR22","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1212\/WNL.0000000000003840","volume":"88","author":"L Rochester","year":"2017","unstructured":"Rochester, L. et al. Decrease in Abeta42 predicts dopa-resistant gait progression in early Parkinson disease. Neurology 88, 1501\u20131511 (2017).","journal-title":"Neurology"},{"key":"431_CR23","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1212\/WNL.0000000000000425","volume":"82","author":"G Alves","year":"2014","unstructured":"Alves, G. et al. CSF Abeta42 predicts early-onset dementia in Parkinson disease. Neurology 82, 1784\u20131790 (2014).","journal-title":"Neurology"},{"key":"431_CR24","doi-asserted-by":"publisher","first-page":"53","DOI":"10.3389\/fnagi.2014.00053","volume":"6","author":"L Parnetti","year":"2014","unstructured":"Parnetti, L. et al. Differential role of CSF alpha-synuclein species, tau, and Abeta42 in Parkinson\u2019s disease. Front. Aging Neurosci. 6, 53 (2014).","journal-title":"Front. Aging Neurosci."},{"key":"431_CR25","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/ene.14032","volume":"27","author":"MG Forland","year":"2020","unstructured":"Forland, M. G. et al. The value of cerebrospinal fluid alpha-synuclein and the tau\/alpha-synuclein ratio for diagnosis of neurodegenerative disorders with Lewy pathology. Eur. J. Neurol. 27, 43\u201350 (2020).","journal-title":"Eur. J. Neurol."},{"key":"431_CR26","first-page":"1277","volume":"70","author":"JH Kang","year":"2013","unstructured":"Kang, J. H. et al. Association of cerebrospinal fluid beta-amyloid 1-42, t-tau, p-tau181, and alpha-synuclein levels with clinical features of drug-naive patients with early Parkinson disease. JAMA Neurol. 70, 1277\u20131287 (2013).","journal-title":"JAMA Neurol."},{"key":"431_CR27","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/ane.13140","volume":"140","author":"XQ Chen","year":"2019","unstructured":"Chen, X. Q. et al. The early diagnosis of Parkinson\u2019s disease through combined biomarkers. Acta Neurol. Scand. 140, 268\u2013273 (2019).","journal-title":"Acta Neurol. Scand."},{"key":"431_CR28","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/S1474-4422(21)00030-2","volume":"20","author":"E Tolosa","year":"2021","unstructured":"Tolosa, E., Garrido, A., Scholz, S. W. & Poewe, W. Challenges in the diagnosis of Parkinson\u2019s disease. Lancet Neurol. 20, 385\u2013397 (2021).","journal-title":"Lancet Neurol."},{"key":"431_CR29","first-page":"1226","volume":"81","author":"B Mollenhauer","year":"2013","unstructured":"Mollenhauer, B. et al. Nonmotor and diagnostic findings in subjects with de novo parkinson disease of the Denopa cohort. Neurobiol 81, 1226\u20131234 (2013).","journal-title":"Neurobiol"},{"key":"431_CR30","first-page":"e206536","volume":"13","author":"SM Dos","year":"2018","unstructured":"Dos, S. M. et al. Evaluation of cerebrospinal fluid proteins as potential biomarkers for early stage Parkinson\u2019s disease diagnosis. PLoS ONE 13, e206536 (2018).","journal-title":"PLoS ONE"},{"key":"431_CR31","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1212\/WNL.0000000000002651","volume":"87","author":"B Mollenhauer","year":"2016","unstructured":"Mollenhauer, B. et al. Monitoring of 30 marker candidates in early Parkinson disease as progression markers. Neurology 87, 168\u2013177 (2016).","journal-title":"Neurology"},{"key":"431_CR32","doi-asserted-by":"publisher","first-page":"g7647","DOI":"10.1136\/bmj.g7647","volume":"350","author":"L Shamseer","year":"2015","unstructured":"Shamseer, L. et al. Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015: elaboration and explanation. BMJ 350, g7647 (2015).","journal-title":"BMJ"},{"key":"431_CR33","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1136\/jnnp.55.3.181","volume":"55","author":"AJ Hughes","year":"1992","unstructured":"Hughes, A. J., Daniel, S. E., Kilford, L. & Lees, A. J. Accuracy of clinical diagnosis of idiopathic Parkinson\u2019s disease: a clinico-pathological study of 100 cases. J. Neurol. Neurosurg. Psychiatry 55, 181\u2013184 (1992).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"431_CR34","doi-asserted-by":"publisher","first-page":"529","DOI":"10.7326\/0003-4819-155-8-201110180-00009","volume":"155","author":"PF Whiting","year":"2011","unstructured":"Whiting, P. F. et al. Quadas-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann. Intern. Med. 155, 529\u2013536 (2011).","journal-title":"Ann. Intern. Med."},{"key":"431_CR35","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins, J. P., Thompson, S. G., Deeks, J. J. & Altman, D. G. Measuring inconsistency in meta-analyses. BMJ 327, 557\u2013560 (2003).","journal-title":"BMJ"}],"updated-by":[{"DOI":"10.1038\/s41531-023-00483-3","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,3,13]],"date-time":"2023-03-13T00:00:00Z","timestamp":1678665600000}}],"container-title":["npj Parkinson's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41531-022-00431-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-022-00431-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-022-00431-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,26]],"date-time":"2023-03-26T15:41:29Z","timestamp":1679845289000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41531-022-00431-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,29]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["431"],"URL":"https:\/\/doi.org\/10.1038\/s41531-022-00431-7","relation":{},"ISSN":["2373-8057"],"issn-type":[{"value":"2373-8057","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,29]]},"assertion":[{"value":"27 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2023","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41531-023-00483-3","URL":"https:\/\/doi.org\/10.1038\/s41531-023-00483-3","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"165"}}